aim immunoTech CEO Equels buys $5,068 in common stock

Thomas K. Equels, CEO and President of AIM ImmunoTech Inc. (NASDAQ:AIM), recently acquired 31,675 shares of the company’s common stock. The transaction, which took place on October 23, 2026, totaled $5,068, with shares purchased at a price of $0.16 each. The purchase comes as the stock trades near its 52-week low of $0.15, down 94% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with shares available on the platform’s most undervalued stocks list.

Mr. Equels, who also serves as a Director, now directly owns 189,747 shares of AIM ImmunoTech common stock following this acquisition.

In other recent news, AIM ImmunoTech Inc. announced a $1.5 million manufacturing agreement with Sterling Pharma Solutions. The agreement involves producing additional batches of the polynucleotide drug substances PolyI and Poly C12U, essential for manufacturing AIM ImmunoTech’s drug product Ampligen. This collaboration, based on existing arrangements from 2022, will take place at Sterling Pharma’s facility in Dudley, UK. Additionally, AIM ImmunoTech’s CEO, Thomas K. Equels, published an article in Breaking Defense discussing Ampligen’s potential as a broad-spectrum antiviral therapeutic. The article highlights Ampligen’s possible applications for Ebola virus disease and COVID-19, though it notes that preclinical findings are not indicative of FDA approval or clinical efficacy. AIM ImmunoTech emphasized the forward-looking nature of the statements regarding future clinical trials and regulatory submissions. These developments reflect AIM ImmunoTech’s ongoing efforts in advancing its antiviral therapeutic strategies.